Reporter-Expressing, Replicating-Competent Recombinant Arenaviruses
Several arenaviruses cause hemorrhagic fever (HF) disease in humans and pose an important public health problem in their endemic regions. To date, no Food and Drug Administration (FDA)-licensed vaccines are available to combat human arenavirus infections, and current anti-arenaviral drug therapy is...
Main Authors: | Luis Martínez-Sobrido, Juan Carlos de la Torre |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-07-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/8/7/197 |
Similar Items
-
Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform
by: Stephen R. Welch, et al.
Published: (2021-06-01) -
Host Cell Factors as Antiviral Targets in Arenavirus Infection
by: Elsa B. Damonte, et al.
Published: (2012-09-01) -
Serological Assays Based on Recombinant Viral Proteins for the Diagnosis of Arenavirus Hemorrhagic Fevers
by: Masayuki Saijo, et al.
Published: (2012-10-01) -
Inhibition of the Type I Interferon Antiviral Response During Arenavirus Infection
by: Juan Carlos de la Torre, et al.
Published: (2010-11-01) -
Animal Models, Prophylaxis, and Therapeutics for Arenavirus Infections
by: Eric Vela
Published: (2012-09-01)